Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. PureTech Share Price
  4. PureTech Share Regulatory News
  5. Transaction in Own Shares

Pin to quick picksPureTech Regulatory News (PRTC)

PureTech Information

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 234.00
Bid: 233.00
Ask: 233.50
Change: 1.50 (0.65%)
Spread: 0.50 (0.215%)
Open: 227.50
High: 234.50
Low: 227.50
Prev. Close: 232.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

21 Dec 2023 07:00

RNS Number : 5312X
PureTech Health PLC
21 December 2023
 

21 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

20 December 2023

Number of ordinary shares purchased:

31,948

Highest price paid per share:

154.80p

Lowest price paid per share:

152.00p

Volume weighted average price paid per share:

154.25p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,517,641 ordinary shares in treasury and has 271,950,518 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 271,950,518 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

20/12/2023

08:01:52

583

154.6

CHIX

00383161287TRLO0.1.1

20/12/2023

08:01:52

583

154.4

BATE

00383161288TRLO0.1.1

20/12/2023

08:01:52

583

154.6

XLON

00383161289TRLO0.1.1

20/12/2023

08:01:52

193

154.6

TRQX

00383161290TRLO0.1.1

20/12/2023

08:01:56

356

154.4

AQXE

00383161302TRLO0.1.1

20/12/2023

09:00:18

583

154.8

CHIX

00383171418TRLO0.1.1

20/12/2023

09:00:18

583

154.8

XLON

00383171419TRLO0.1.1

20/12/2023

09:02:41

583

153.6

XLON

00383171777TRLO0.1.1

20/12/2023

10:43:29

356

154.2

AQXE

00383188137TRLO0.1.1

20/12/2023

10:43:29

583

154

BATE

00383188139TRLO0.1.1

20/12/2023

10:43:29

583

154.2

CHIX

00383188138TRLO0.1.1

20/12/2023

10:43:29

415

154.2

XLON

00383188140TRLO0.1.1

20/12/2023

10:43:29

1334

154.2

XLON

00383188141TRLO0.1.1

20/12/2023

10:43:29

45

153.8

TRQX

00383188142TRLO0.1.1

20/12/2023

10:43:29

148

153.8

TRQX

00383188143TRLO0.1.1

20/12/2023

10:43:29

2

153.8

TRQX

00383188144TRLO0.1.1

20/12/2023

10:43:29

8

153.8

TRQX

00383188145TRLO0.1.1

20/12/2023

10:43:29

6

153.8

TRQX

00383188146TRLO0.1.1

20/12/2023

10:56:34

338

154

CHIX

00383190461TRLO0.1.1

20/12/2023

11:11:09

471

154.2

CHIX

00383192812TRLO0.1.1

20/12/2023

11:23:19

112

154.2

CHIX

00383194421TRLO0.1.1

20/12/2023

11:25:29

19

153.8

BATE

00383194647TRLO0.1.1

20/12/2023

11:27:50

363

153.8

BATE

00383194887TRLO0.1.1

20/12/2023

11:28:30

201

153.8

BATE

00383194956TRLO0.1.1

20/12/2023

11:28:30

583

153.8

CHIX

00383194957TRLO0.1.1

20/12/2023

11:29:55

823

153.4

XLON

00383195253TRLO0.1.1

20/12/2023

11:29:55

343

153.4

XLON

00383195254TRLO0.1.1

20/12/2023

11:52:12

533

152.2

CHIX

00383198720TRLO0.1.1

20/12/2023

11:52:12

1749

152.2

XLON

00383198721TRLO0.1.1

20/12/2023

11:52:12

433

152

XLON

00383198722TRLO0.1.1

20/12/2023

11:52:13

13

152

XLON

00383198723TRLO0.1.1

20/12/2023

12:37:56

16

153

XLON

00383205119TRLO0.1.1

20/12/2023

12:39:35

1200

153.8

XLON

00383205315TRLO0.1.1

20/12/2023

12:39:35

549

153.8

XLON

00383205316TRLO0.1.1

20/12/2023

13:01:54

3036

154.4

XLON

00383209664TRLO0.1.1

20/12/2023

13:01:55

105

154.4

CHIX

00383209672TRLO0.1.1

20/12/2023

13:01:55

773

154.4

CHIX

00383209673TRLO0.1.1

20/12/2023

14:40:57

356

154.8

AQXE

00383243718TRLO0.1.1

20/12/2023

14:40:57

583

154.8

CHIX

00383243720TRLO0.1.1

20/12/2023

14:40:57

583

154.8

BATE

00383243719TRLO0.1.1

20/12/2023

14:40:57

177

154.8

TRQX

00383243721TRLO0.1.1

20/12/2023

14:40:57

237

154.8

XLON

00383243722TRLO0.1.1

20/12/2023

14:40:57

144

154.8

XLON

00383243723TRLO0.1.1

20/12/2023

14:40:57

184

154.8

XLON

00383243725TRLO0.1.1

20/12/2023

14:40:57

18

154.8

XLON

00383243724TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243726TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243727TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243728TRLO0.1.1

20/12/2023

14:40:57

583

154.8

XLON

00383243729TRLO0.1.1

20/12/2023

14:40:57

539

154.8

XLON

00383243730TRLO0.1.1

20/12/2023

14:40:57

607

154.8

XLON

00383243731TRLO0.1.1

20/12/2023

14:40:57

20

154.8

XLON

00383243732TRLO0.1.1

20/12/2023

15:49:32

356

154.8

AQXE

00383277253TRLO0.1.1

20/12/2023

15:49:32

583

154.8

BATE

00383277254TRLO0.1.1

20/12/2023

15:49:32

1166

154.8

CHIX

00383277256TRLO0.1.1

20/12/2023

15:49:32

193

154.8

TRQX

00383277258TRLO0.1.1

20/12/2023

15:49:32

596

154.8

XLON

00383277259TRLO0.1.1

20/12/2023

15:49:32

729

154.8

XLON

00383277260TRLO0.1.1

20/12/2023

15:49:32

2756

154.8

XLON

00383277261TRLO0.1.1

20/12/2023

15:49:32

583

154.8

XLON

00383277262TRLO0.1.1

20/12/2023

15:57:29

19

154.4

AQXE

00383281074TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTFVLIFIV
101112131415161718
Date   Source Headline
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing
21st Oct 20201:03 pmRNSAkili Presents New Data on EndeavorRx at AACAP
20th Oct 20201:08 pmRNSVor Appoints Biotech Leader Matt Patterson to BOD
12th Oct 20201:00 pmRNSNew Vedanta VE202 Data Presented at UEG Week
7th Oct 20201:03 pmRNSAkili Adds Award-Winning Marketing Leader as CMO
5th Oct 202012:00 pmRNSAlivio Awarded $3.3M from DoD to Advance ALV-304
1st Oct 20207:05 amRNSPureTech Appoints Biocon Founder Kiran Shaw to BOD
1st Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20202:00 pmRNSBARDA Awards Vedanta Up to $76.9M to Advance VE303
29th Sep 202012:00 pmRNSAlivio Adds Dr Harry Leider to Board of Directors
25th Sep 20204:35 pmRNSPrice Monitoring Extension
23rd Sep 20207:00 amRNSPureTech Nasdaq Listing Progresses
18th Sep 20204:41 pmRNSSecond Price Monitoring Extn
18th Sep 20204:35 pmRNSPrice Monitoring Extension
18th Sep 202010:15 amRNSPrice Monitoring Extension
16th Sep 20201:00 pmRNSVedanta Appoints Drug Development Leader as CMO
4th Sep 202012:42 pmRNSGelesis Presents Plenity Efficacy and Safety Data
4th Sep 202012:07 pmRNSSecond Price Monitoring Extn
4th Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20204:40 pmRNSSecond Price Monitoring Extn
28th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Aug 20207:00 amRNSHalf-year Report
26th Aug 20201:02 pmRNSVor Appoints John King as Chief Commercial Officer
26th Aug 202012:40 pmRNSPRTC Receives $100M from Founded Entity Shares
26th Aug 202012:08 pmRNSPublication of Shareholder Circular
25th Aug 20202:05 pmRNSSonde Makes Acquisition in Vocal Biomarker Space
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20207:00 amRNSPureTech to Present at Wedbush PacGrow Conference
3rd Aug 20207:00 amRNSTotal Voting Rights
30th Jul 20201:02 pmRNSVor Appoints Life Science Leader to BOD
30th Jul 202012:07 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 202012:08 pmRNSSecond Price Monitoring Extn
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
101112131415161718

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.